DGAP-News: Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations

        Print
| Source: EQS Group AG
DGAP-News: Novavax, Inc. /
Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process
Development Operations

07.04.2014 / 18:42

---------------------------------------------------------------------

GAITHERSBURG, Md., 2014-04-07 18:42 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced the appointment of Cynthia N. Oliver,
Ph.D. to the position of Senior Vice President, Process Development Operations,
effective April 8, 2014. Dr. Oliver will be responsible for all process
development activities, with a specific focus on the company's RSV F-protein
nanoparticle, seasonal influenza and pandemic influenza vaccine candidates. 

Dr. Oliver has been a consultant of Novavax since 2011 where her significant
expertise and experiences have helped the Company formulate and execute on
critical process development strategies. From 1993 until 2010, Dr. Oliver held
a variety of positions, including Vice President, Process Biochemistry and
Formulation Sciences at Medimmune, Inc., with responsibilities that included
vaccines, proteins, monoclonal antibodies and small molecules, including the
commercial products Synagis(r) and FluMist(r). Prior to MedImmune, she had
similar 
responsibilities at Merck Research Laboratories, and spent a number of years
working at the National Institutes of Health in the National Heart, Lung and
Blood Institute. She earned her doctorate from Johns Hopkins, her masters from
University of Massachusetts, and her bachelor's degree from Connecticut
College. 

'At Novavax, successful process development is critical to the ongoing
development of our novel vaccines and it serves as the foundation upon which a
consistent, GMP commercial manufacturing process is built. Cindy's extensive
experience, industry knowledge and managerial aptitude complement our ongoing
efforts to bring our RSV, seasonal influenza and pandemic influenza vaccine
candidates to licensure,' said Stan Erck, President and CEO of Novavax, Inc.
'After working with us as a consultant for three years, I am delighted that
Cindy has agreed to join Novavax to lead our process development efforts.' 

Dr. Oliver remarked, 'Novavax' progress and success in Phase 2 clinical trials
evidences its commitment to bringing important, and in the case of RSV,
industry-leading vaccines to the market. I have been delighted to consult with
Novavax to this stage, and am equally delighted to head up our efforts to
develop safe, high quality vaccines and state-of-the-art vaccine production.
Novavax' approach to developing these and other, earlier-stage preclinical
vaccine candidates, has tremendous commercial potential, and I am honored to
lead the process development function that supports this exciting technology.' 

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
novavax.com. 

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward-looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those expressed or implied by such statements. These risks and uncertainties
include those identified under the heading 'Risk Factors' in the Novavax Annual
Report on Form 10-K for the year ended December 31, 2013, and filed with the
Securities and Exchange Commission (SEC). Investors are cautioned not to place
considerable reliance on the forward-looking statements contained in this press
release. You are encouraged to read company filings with the SEC, available at
sec.gov, for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of the date of
this document, and the company undertakes no obligation to update or revise any
of the statements. The company's business is subject to substantial risks and
uncertainties, including those referenced above. Investors, potential
investors, and others should give careful consideration to these risks and
uncertainties. 


         CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

07.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     Novavax, Inc.  
 
 
             United States  
ISIN:        US6700021040   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
262050 07.04.2014